[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-378455-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-378455-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","therapeutic-avenues-for-t-cells-in-cancer","Therapeutic avenues for γδ T cells in cancer","","γδ T cells are regarded as promising effector lymphocytes for next-generation cancer immunotherapies. Despite their relative rarity in human peripheral blood, they are more abundant in epithelial tissues where many tumors develop, and they actively support anticancer immunity as cytotoxic cells or as “type 1” immune orchestrators. Their key advantage is independence from antigen presentation via the MHC, distinguishing them from conventional αβ T cells. The review discusses main human γδ T cell therapeutic strategies, including bispecific engagers and adoptive cell therapies targeting Vδ1+ or Vδ2+ subsets, and summarizes preclinical and clinical evidence for solid and hematological malignancies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/therapeutic-avenues-for-t-cells-in-cancer/378455/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/therapeutic-avenues-for-t-cells-in-cancer/378455.png","ImageObject",300,407,{"name":42,"@type":43},"Ben ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are γδ T cells considered promising for cancer immunotherapy?","Question",{"text":63,"@type":64},"They actively participate in anticancer immunity as cytotoxic cells or immune orchestrators and offer a major advantage: independence from antigen presentation via the MHC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What distinguishes γδ T cells from conventional αβ T cells in the context of antigen presentation?",{"text":68,"@type":64},"γδ T cells do not rely on antigen presentation through the major histocompatibility complex (MHC), which clearly sets them apart from αβ T cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic strategies are reviewed for γδ T cell-based treatments?",{"text":72,"@type":64},"The review covers antibody-based bispecific engagers and adoptive cell therapies, focused on either the Vδ1+ or Vδ2+ γδ T-cell subsets, along with related preclinical data and clinical trials.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},378455,1790294635,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Open access Review  \n Therapeutic avenues for γδ T cells in cancer  \nGonçalo Palrão Costa,1 Sofia Mensurado,2 Bruno Silva-Santos  1,2  \nTo cite: Costa GP, Mensurado S, Silva-Santos B. Therapeutic avenues for γδ T cells in cancer. Journal for ImmunoTherapy of Cancer 2023;11:e007955 . doi:10.1136/jitc-2023-007955  \nSM and BS-S contributed equally.  \nAccepted 28 October 2023  \n© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \n1Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal  \n2Instituto de Medicina Molecular João Lobo Antunes, Faculadede Medicina, Universidade de Lisboa, Lisbon, Portugal  \nCorrespondence to  \nDr Sofia Mensurado;  \nsofiamensurado@medicina. [ulisboa.pt](ulisboa.pt)  \nDr Bruno Silva-Santos;  \n[bssantos@medicina.ulisboa.pt](bssantos@medicina.ulisboa.pt)  \nABSTRACT  \nγδ T cells are regarded as promising effector lymphocytes for next-generation cancer immunotherapies. In spite of being relatively rare in human peripheral blood, γδ T cells are more abundant in epithelial tissues where many tumors develop, and have been shown to actively participate in anticancer immunity as cytotoxic cells or as “type 1” immune orchestrators. A major asset of γδ T cells for tackling advanced cancers is their independence from antigen presentation via the major histocompatibility complex, which clearly sets them apart from conventional αβ T cells. Here we discuss the main therapeutic strategies based on human γδ T cells. These include antibody-based bispecific engagers and adoptive cell therapies, either focused on the Vδ1+ or Vδ2+ γδ T-cell subsets, which can be expanded selectively and differentiated or engineered to maximize their antitumor functions. We review the preclinical data that supports each of the therapeutic strategies under development; and summarize the clinical trials being pursued towards establishing γδ T cell-based treatments for solid and hematological malignancies.  \nINTRODUCTION  \nCancer immunotherapies have recently produced major advances in the treatment of both solid and hematological tumors. In particular, immune checkpoint blockade (ICB) has been successfully implemented in various advanced solid cancers, most notably melanoma and lung carcinoma1; and T cells expressing chimeric antigen receptors (CAR-T cells) have changed the paradigm in the treatment of B-cell-derived neoplasms.2 This notwithstanding, many indications and large proportions of patients still lack efficacious immunotherapies, which are now the  \nmajor challenge in immuno-oncology.  \nOne of the key concepts towards improving the clinical application of immunotherapy is to tackle immune evasion mechanisms that result from the dynamic interaction between cancer and immune cells. A major immune evasion strategy found in advanced cancers is the downregulation of major histocompatibility complex (MHC; also known as human leukocyte antigen, HLA) molecules, which are required for αβ T-cell activation on presentation of somatically mutated  \n“neoantigens” to αβ T-cell receptors (TCR) .3 However, this limitation does not apply to γδ TCR-expressing T cells (γδ T cells), which despite being rare in the human peripheral blood, are enriched in epithelial tissues where many cancers develop, and have been shown to actively participate in antitumor immunity.4  \nγδ T cells make up a small fraction, ranging from 1% to 10%, of the total human CD3+ T-cell population. These cells express a lineage-specific TCR, containing one of seven Vγ chain isotypes (Vγ2, 3, 4, 5, 8, 9, and 11) paired with one of four Vδ chain types (Vδ1, 2, 3, and 5), which can be highly diverse due to the stochastic nature of the TCR somatic recombination process.5 The most common pairing consists in the Vγ9Vδ2 TCR that has the particularity of sensing the intracellular accumulation of non-peptidic phosphoantigens (PAg) in target cells. Such an accumulation can either be naturally fou","cbCairDj0RvIFEuE","https://ap.wps.com/l/cbCairDj0RvIFEuE","pdf",677852,"English","# Abstract\n# Introduction\n## Immune checkpoint blockade and CAR-T advances\n## Immune evasion via MHC downregulation\n## Features and subsets of γδ T cells (Vγ/Vδ pairing)\n## Phosphoantigen sensing and BTN3A1/CD277\n## NK receptors and cytotoxic mechanisms\n## Indirect antitumor immune responses","[{\"question\":\"Why are γδ T cells considered promising for cancer immunotherapy?\",\"answer\":\"They actively participate in anticancer immunity as cytotoxic cells or immune orchestrators and offer a major advantage: independence from antigen presentation via the MHC.\"},{\"question\":\"What distinguishes γδ T cells from conventional αβ T cells in the context of antigen presentation?\",\"answer\":\"γδ T cells do not rely on antigen presentation through the major histocompatibility complex (MHC), which clearly sets them apart from αβ T cells.\"},{\"question\":\"What therapeutic strategies are reviewed for γδ T cell-based treatments?\",\"answer\":\"The review covers antibody-based bispecific engagers and adoptive cell therapies, focused on either the Vδ1+ or Vδ2+ γδ T-cell subsets, along with related preclinical data and clinical trials.\"}]","Therapeutic avenues for γδ T cells in cancer | PDF",1790230151]